Despite Boehringer Ingelheim’s 2021 Humira biosimilar approval being heralded by some analysts as a “landmark achievement” for the field, the
Excitement grows as the FDA’s first approval for MASH treatment nears commercialization, according to Spherix Global Insights. Exton, PA., April
Takeda’s line extension has outpaced other concurrent launches in adoption and familiarity three months post launch, according to Spherix Global
Research conducted by Spherix Global Insights reveals Retinal Specialists likely to adopt gene therapies. Exton, PA., March 19, 2024 –
Spherix Global Insights’ fourth annual IgAN patient chart audit reveals continued shifts in the IgAN treatment paradigm with the use
Spherix Global Insights captures neurologists’ reactions within 48 hours of these pivotal announcements. EXTON, PA., March 12, 2024 — For
Although crowded, the RA market contains clear pathways for existing players and new entrants to navigate the evolving landscape and
Adoption of Leqembi is even slower than expected. EXTON, PA., February 22, 2024 — The 2023 announcement of newly approved
Earlier screening will be needed in the age of biomarkers. EXTON, PA., February 16, 2024 — Millions of people worldwide
Navigating the landscape of Wet AMD Therapies During AMD Awareness Month EXTON, PA., February 8, 2024 — As Age-Related Macular
The addition of UCB’s Bimzelx in the EU and pending US approval adds to the growing momentum of the class,
[Exton, PA., January 18, 2024]—Colleagues from Spherix Global Insights partnered with Cheeriodicals to assemble and deliver care packages to dialysis
